Education
About Us
Working with TipRanks
Follow Us
Annexon Biosciences (ANNX)
NASDAQ:ANNX
ANNX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.30 - $8.40
Previous CloseN/A
Volume252.73K
Average Volume (3M)1.39M
Market Cap
$296.22M
Enterprise Value$517.89M
Total Cash (Recent Filing)$49.50M
Total Debt (Recent Filing)$28.97M
Price to Earnings (P/E)―
Beta1.46
Next Earnings
May 19, 2025EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.01
Shares Outstanding109,709,820
10 Day Avg. Volume1,945,262
30 Day Avg. Volume1,387,511
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)169.36
Price to Cash Flow (P/CF)-1.80
P/FCF Ratio0.00
Enterprise Value/Market Cap1.75
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.41
Forecast
1Y Price Target
$14.20Price Target Upside491.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
Annexon Biosciences News
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessANX005's pivotal Phase II/III trial in GBS succeeded, showing better outcomes than the current treatments.
Market PotentialANX005's potential FDA approval in Guillain-Barré Syndrome could lead to significant market share due to its advantages over the current treatment.
Regulatory ProspectsANX005 is expected to be approved by the FDA and to become the new standard of care for GBS.
Bears Say
Price Target ReductionRevaluation of opex assumption and US and EU penetration assumptions for the GBS program reduced the price target.
Stock PerformanceShares are down -55% YTD as additional regulatory clarity on ANX005 in GBS and ANX1502's POC data is awaited.
---
Ownership Overview
13.86% Insiders
16.25% Mutual Funds
0.51% Other Institutional Investors
44.86% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ANNX FAQ
What was Annexon Biosciences’s price range in the past 12 months?
Annexon Biosciences lowest stock price was $2.30 and its highest was $8.40 in the past 12 months.
What is Annexon Biosciences’s market cap?
Annexon Biosciences’s market cap is $296.22M.
When is Annexon Biosciences’s upcoming earnings report date?
Annexon Biosciences’s upcoming earnings report date is May 19, 2025 which is in 55 days.
How were Annexon Biosciences’s earnings last quarter?
Annexon Biosciences released its earnings results on Mar 03, 2025. The company reported -$0.33 earnings per share for the quarter, missing the consensus estimate of -$0.27 by -$0.06.
Is Annexon Biosciences overvalued?
According to Wall Street analysts Annexon Biosciences’s price is currently Undervalued.
Does Annexon Biosciences pay dividends?
Annexon Biosciences does not currently pay dividends.
What is Annexon Biosciences’s EPS estimate?
Annexon Biosciences’s EPS estimate is -0.3.
How many shares outstanding does Annexon Biosciences have?
Annexon Biosciences has 109,709,820 shares outstanding.
What happened to Annexon Biosciences’s price movement after its last earnings report?
Annexon Biosciences reported an EPS of -$0.33 in its last earnings report, missing expectations of -$0.27. Following the earnings report the stock price went down -9.47%.
Which hedge fund is a major shareholder of Annexon Biosciences?
Currently, no hedge funds are holding shares in ANNX
---
Annexon Biosciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.20 (491.67% Upside)
$14.20 (491.67% Upside)
Blogger Sentiment
Bullish
ANNX Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 2.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $126.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.8%
Last 30 Days ▲ 29.6%
Last 30 Days ▲ 29.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-60.29%
12-Months-Change
Fundamentals
Return on Equity
-50.84%
Trailing 12-Months
Asset Growth
17.60%
Trailing 12-Months
Company Description
Annexon Biosciences
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.
---
ANNX Stock 12 Month Forecast
Average Price Target
$14.20
▲(491.67% Upside)
Technical Analysis
Alnylam Pharma
―
Ionis Pharmaceuticals
―
Vertex Pharmaceuticals
―
Ultragenyx Pharmaceutical
―
Crispr Therapeutics AG
―
Best Analysts Covering ANNX
1 Year
1 Year Success Rate
5/13 ratings generated profit
1 Year Average Return
+0.12%
reiterated a buy rating 23 days ago
Copying Andrew Fein's trades and holding each position for 1 Year would result in 38.46% of your transactions generating a profit, with an average return of +0.12% per trade.
---